Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients

BACKGROUND: The anti–programmed cell death 1 (anti–PD-1) antibody pembrolizumab is clinically active against non–small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also expre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Lin, Mao, Luo, Haihua, Liang, Shuzhen, Chen, Jibing, Liu, Aihua, Niu, Lizhi, Jiang, Yong
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190908/
https://ncbi.nlm.nih.gov/pubmed/32027620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132712
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars